Dr. Amy Barton Pai, Pharm.D., BCPS, FASN, FCCP, FNKF is Associate Professor of Clinical Pharmacy at the University of Michigan College of Pharmacy. She obtained her Bachelors of Science in Pharmacy from Albany College of Pharmacy in 1996 and then completed a Pharmacy Practice Residency at St. Peter’s Hospital in Albany, New York. She received her Doctor of Pharmacy from Albany College of Pharmacy in 1999. From 1999-2001 she was a Nephrology Research Fellow at the University of Illinois at Chicago. Dr. Pai was on faculty at the University of New Mexico College of Pharmacy and School of Medicine from 2001 to 2008 and at Albany College of Pharmacy and Health Sciences from 2008 to 2016.
Her clinical and translational research program focuses on oxidative stress and inflammation in chronic kidney disease (CKD) patients. Her laboratory conducts in vivo and in vitro investigations of the effects intravenous iron nanoparticle formulations, vitamin D and other pharmaceuticals on cytokine activation, reactive oxygen species formation and lipid peroxidation to better understand the potential effects of the agents on vascular disease in patients with kidney disease. Other research interests include pharmacokinetics and drug metabolism in CKD, effects of iron on Gram-positive organism growth and infection, reducing preventable harm from nephrotoxic medications and outcomes related to clinical pharmacy interventions in CKD patients. She is also dedicated to training future Clinical Pharmacy Scientists.
Bioequivalence challenges with intravenous iron-carbohydrate nanoparticle formulations
Differential safety, toxicity and biodistribution profiles of commercially available intravenous iron formulations in chronic kidney disease
Innovative strategies to reduce preventable harm from nephrotoxic medications (e.g. non-steroidal antiinflammatory drugs)
Evaluation of advanced practice models in kidney disease that include pharmacists
- 2016 Service Award
Pai AB, Meyer D, Bales B, Cotero V, Pai MP, Zheng N, Jiang W. Performance of redox active and chelatable iron assays to determine labile iron release for intravenous iron formulations. Clin Transl Sci. 2017 Feb 3. PMID:28160427
Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S, On behalf of the American Society of Nephrology Dialysis Advisory Group. Considerations and Challenges in Defining the Optimal Utilization of Iron in Dialysis-Dependent Chronic Kidney Disease. J Am Soc Nephrol. 2015;26(6):1238-1247 PMID:25542967
Pai AB. Evaluating Plasma Pharmacokinetics of IV Iron Formulations: Judging Books by Their Covers? Clin Pharmacokinet 2015:54(4);323-4
Pai AB, McQuade C, Olp J. Hicks P, Conner T. Non-transferrin Bound Iron (NTBI), Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). Biometals. 2011 Aug;24(4):603-13 PMID: 21229380
Jang S, Prokopienko AJ, Grabe DW, Cerulli J, Fox C, Vassalotti J, Pai AB. NSAID-Avoidance Education in Community Pharmacies for Patients at High Risk for Acute Kidney Injury, Upstate New York, 2011. Prev Chronic Dis. 2014 Dec 18;11:E220 PMID:25523351
Pai AB, Depczynski JC, Martinez I, Boyd A, Khan N, Manley HJ. Reduced Drug Use Hospitalization Rates in Patients Undergoing Hemodialysis Who Received Pharmaceutical Care-a 2 year randomized, controlled study. Pharmacotherapy 2009;29(12):1433-1440 PMID: 19947803